Kairos Pharma to Participate in The Microcap Conference in January 2025
Kairos Pharma (NYSE American:KAPA), a clinical stage biotechnology company, has announced its upcoming participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. During the conference, the company's management team will deliver a corporate presentation and conduct one-on-one meetings with institutional and individual investors to discuss recent developments, growth strategy, and investment opportunities.
Kairos Pharma (NYSE American:KAPA), un'azienda biotecnologica in fase clinica, ha annunciato la sua prossima partecipazione a The Microcap Conference 2025. L'evento si svolgerà dal 28 al 30 gennaio 2025, presso il Borgata Hotel Spa & Casino ad Atlantic City, NJ. Durante la conferenza, il team di gestione dell'azienda presenterà una relazione aziendale e condurrà incontri individuali con investitori istituzionali e privati per discutere gli sviluppi recenti, la strategia di crescita e le opportunità di investimento.
Kairos Pharma (NYSE American:KAPA), una empresa biotecnológica en etapa clínica, ha anunciado su próxima participación en The Microcap Conference 2025. El evento se llevará a cabo del 28 al 30 de enero de 2025, en el Borgata Hotel Spa & Casino en Atlantic City, NJ. Durante la conferencia, el equipo de gestión de la compañía presentará una exposición corporativa y realizará reuniones uno a uno con inversores institucionales y privados para discutir desarrollos recientes, estrategia de crecimiento y oportunidades de inversión.
카이로스 제약 (NYSE American:KAPA), 임상 단계 생명공학 회사,가 2025 마이크로캡 컨퍼런스에 곧 참여할 것이라고 발표했습니다. 이 행사는 2025년 1월 28일부터 30일까지 뉴저지주 애틀랜틱 시티의 보르가타 호텔 스파 & 카지노에서 열립니다. 컨퍼런스 동안 회사의 경영진은 기업 발표를 하고 기관 투자자 및 개인 투자자와 일대일 회의를 진행하여 최근 발전 상황, 성장 전략 및 투자 기회에 대해 논의할 것입니다.
Kairos Pharma (NYSE American:KAPA), une entreprise de biotechnologie en phase clinique, a annoncé sa prochaine participation à la Microcap Conference 2025. L'événement se déroulera du 28 au 30 janvier 2025, au Borgata Hotel Spa & Casino à Atlantic City, NJ. Lors de la conférence, l'équipe de direction de l'entreprise fera une présentation d'entreprise et mènera des réunions individuelles avec des investisseurs institutionnels et particuliers pour discuter des développements récents, de la stratégie de croissance et des opportunités d'investissement.
Kairos Pharma (NYSE American:KAPA), ein biopharmazeutisches Unternehmen in klinischer Phase, hat seine bevorstehende Teilnahme an der Microcap-Konferenz 2025 bekannt gegeben. Die Veranstaltung findet vom 28. bis 30. Januar 2025 im Borgata Hotel Spa & Casino in Atlantic City, NJ, statt. Während der Konferenz wird das Management-Team des Unternehmens eine Unternehmenspräsentation halten und Einzelgespräche mit institutionellen und privaten Investoren führen, um über die jüngsten Entwicklungen, die Wachstumsstrategie und die Investitionsmöglichkeiten zu diskutieren.
- None.
- None.
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
Kairos Pharma's management team will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
About The Microcap Conference 2025
The Microcap Conference is the largest independent microcap event in the U.S., bringing together top-tier investors and executives from microcap companies. The event offers a platform for companies to showcase their value propositions through presentations, one-on-one meetings, and networking opportunities.
The 2025 event will feature:
Keynote Speakers: Renowned industry figures, including Jon Ledecky, Co-Owner of the New York Islanders, who will engage in a fireside chat with CNBC's Bob Pisani; plus Tom Gardner, CEO of Motley Fool, who will share insights on investing, market trends, and entrepreneurial success.
Expert Panels and Presentations: Financial commentators Ron Insana (CNBC) and Charlie Gasparino (FOX Business) will cover critical topics for the US equity markets, from capital formation to regulatory updates and market trends.
Entertainment Headliner: A special performance by Tom Papa, celebrated comedian and host of Netflix specials, ensuring a memorable evening for attendees.
Hosted by DealFlow Events, The Microcap Conference is renowned for its blend of high-quality content, engaging networking, and exceptional entertainment. For more information, visit https://themicrocapconference.com.
About Kairos Pharma Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American:KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105-a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com.
Contact:
CORE IR
Louie Toma
investors@kairospharma.com
SOURCE: Kairos Pharma Ltd.
View the original press release on accesswire.com
FAQ
When is Kairos Pharma (KAPA) presenting at The Microcap Conference 2025?
What will Kairos Pharma (KAPA) discuss at The Microcap Conference 2025?
Where will The Microcap Conference 2025 featuring Kairos Pharma (KAPA) be held?
Will Kairos Pharma (KAPA) offer one-on-one meetings at The Microcap Conference 2025?
